February 1, 2017
(Bloomberg) – Mylan NV set off a firestorm in Congress last year over skyrocketing prices of its EpiPen. Now it’s facing a U.S. antitrust investigation over whether it improperly thwarted competition to the blockbuster product. The company has received a request for information from the Federal Trade Commission as part of a preliminary investigation, it said Monday in response to a query from Bloomberg. It said it hasn’t acted improperly to prevent generic competition.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.